Virtual Library

Start Your Search

Corina Bello



Author of

  • +

    P2.09 - Pathology (ID 174)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Pathology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.09-19 - Effect of Neoadjuvant (Radio)chemotherapy on PD-L1 Expression in Resected Non-Small Cell Lung Cancers (ID 366)

      10:15 - 18:15  |  Author(s): Corina Bello

      • Abstract
      • Slides

      Background

      Programmed cell death ligand 1 (PD-L1) expression has been established as a predictive biomarker for checkpoint-inhibitor treatment in advanced non-small-cell lung carcinomas (NSCLC). Inclusion of PD1/PD-L1 inhibitors into existing neoadjuvant regimens is currently evaluated in clinical trials. However, data on the impact of neoadjuvant regimens on tumoral PD-L1 expression is rare. We aimed to assess the PD-L1 expression in NSCLC before/after neoadjuvant treatment, including its prognostic relevance.

      Method

      Our single-center, retrospective study cohort comprised 131 consecutive patients with NSCLC resected after neoadjuvant therapy, diagnosed 2000-2016, including 63 available pretreatment biopsies. Tumor types comprised 59 squamous cell carcinomas (SQCC), 66 adenocarcinomas (ADC) and 7 others. The pathological slides and clinical records were reevaluated assessing tumor-size according to current IASLC-recommendations by multiplying the vital tumor percentage with the macroscopic tumor bed. Biologically matched cohorts of 60 locally advanced (pN2) primary resected ADC and 54 SQCC served as controls. PD-L1 was immunohistochemically stained using the Ventana SP263 KIT and tumoral expression was assessed on whole slides by two investigators using the increments: <1%, 1-<25%, 25-<50%, 50%. The results were correlated with clinico-pathological parameters.

      Result

      PD-L1 could be evaluated in 112 specimens after neoadjuvant chemotherapy, including 24 following neoadjuvant radiochemotherapy: 53 cases scored <1%, 31 1-<25%, 4 25-<50% and 24 ≥50%. In pre-treatment biopsies, 50/63 (79.4%) cases scored <50%, 13/63 (20.6%) ≥50%. Eight/63 (12.7%) cases were discordant regarding the clinically relevant cut-off 50%, 4 cases (2 ADC, 2 SQCC) having a higher expression and 4 cases (2 ADC, 2 SQCC) with lower expression after neoadjuvant radiochemotherapy.

      PD-L1 expression was significantly higher in primary resected SQCC (n=53) compared to neoadjuvantly treated SQCC (n=52, p=0.014; n=41 neoadjuvant chemotherapy only, p=0.033), with 14 cases scoring <1%, 21 1-<25%, 4 25-49% and 14≥50%.

      There was no significant difference regarding PD-L1 expression for the paired ADC-groups.

      In neoadjuvantly treated NSCLC, there was no correlation between PD-L1 expression (increments or 50% cut-off) and ypT, ypN, UICC/AJCC-stage, histological tumor regression, tumor size or the size of the tumor bed. PD-L1 expression was not associated with overall survival nor progression free survival in any cohort.

      Conclusion

      We document a discordance of 12.7% regarding the cut-off 50% between pre-treatment biopsies and resections after neoadjuvant therapy, which may be due to tumor-heterogeneity. The higher PD-L1 expression in primary resected SQCC compared to SQCC resected after treatment provides evidence that the influence of neoadjuvant therapy on PD-L1 expression might depend on the histological tumor type.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.